Abstracts tagged "autoimmune diseases"

Abstract Number: 152 • 2017 Pediatric Rheumatology Symposium
Characteristics of Patients With Juvenile Idiopathic Arthritis in a US Healthcare Claims Database
TA Simon¹, A Baheti², N Ray², S Kelly¹ and Z Guo¹, ¹Bristol-Myers Squibb, Princeton, NJ, ²Mu Sigma, Bangalore, India
Background/Purpose: Abatacept, the first selective co-stimulation modulator approved and used for the treatment of juvenile idiopathic arthritis (JIA), has a mechanism of action that is…
Abstract Number: 147 • 2017 Pediatric Rheumatology Symposium
Epigenetic and Transcriptomic Profiling of Primary Juvenile Idiopathic Arthritis Patient Cells: Better Understanding of Disease Pathogenesis
Lucas Picavet¹, Janneke Peeters², Sandra Coenen³, Arjan Boltjes⁴, Femke van Wijk⁵, Paul Coffer², Bas Vastert⁶ and Jorg van Loosdregt⁷, ¹Regenerative Medicine Center Utrecht, University Medical Center Utrecht, Utrecht, Netherlands, ²Center for Molecular Medicine and Regenerative Medicine Center Utrecht, University Medical Center Utrecht, Utrecht, Netherlands, ³University Medical Center Utrecht, Utrecht, Netherlands, ⁴Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Laboratory for Translational Immunity, University Medical Center Utrecht, Utrecht, Netherlands, ⁶Division of Pediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands, ⁷Division of Pediatrics, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: For many autoimmune diseases, including Juvenile Idiopathic Arthritis (JIA), the molecular mechanisms remain elusive. JIA can be used as a model to study autoimmune…
Abstract Number: 12L • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Atacicept in Patients with Systemic Lupus Erythematosus: Results of a 24-Week Randomized, Placebo-Controlled, Phase IIb Study
Joan T. Merrill¹, Daniel J. Wallace², Stephen Wax³, Amy Kao⁴, Patricia Fraser⁴, Wai Chin⁴ and David A. Isenberg⁵, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of California Los Angeles, Los Angeles, CA, ³EMD Serono, BIllerica, MA, ⁴EMD Serono, Billerica, MA, ⁵University College Hospital, London, London, United Kingdom

Background/Purpose: Atacicept targets B-cell stimulating factors BLyS and APRIL. In the APRIL-SLE trial, atacicept 150 mg was associated with reduced SLE flares in post-hoc analyses.1Methods:…
Abstract Number: 2175 • 2016 ACR/ARHP Annual Meeting
Comparisons of Patients Prescribed Biosimilars or BIO-Originators for Autoimmune Diseases in Germany
Sumesh Kachroo¹, Christopher Black¹, Emma Sullivan², John Waller² and James Piercy², ¹CORE, Merck & Co., Inc., Kenilworth, NJ, ²Adelphi Real World, Manchester, United Kingdom
Background/Purpose: To compare the characteristics of patients who receive biosimilars against patients receiving bio-originators. Methods: The Adelphi Biosimilars Programme 2016 is a cross-sectional survey of…
Abstract Number: 2428 • 2016 ACR/ARHP Annual Meeting
Autoantibody Diversity in Pediatric Patients Undergoing Evaluation for Autoimmune Encephalitis: A Retrospective Investigation
Anne E Tebo¹, Thomas Haven², Aimee O. Hersh³ and Eyal Muscal⁴, ¹Pathology, University of Utah School of Medicine and ARUP Laboratories, Salt Lake City, UT, ²Department of Pathology, University of Utah, ARUP Institute of Clinical and Experimental Pathology, Salt Lake City, UT, ³Pediatrics/Rheumatology, University of Utah, Salt Lake City, UT, ⁴Immunology, allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Antibodies directed against N-methyl-D-aspartate type glutamate receptor (NMDAR), voltage-gated potassium channel (VGKC) or glutamic acid decarboxylase (GAD65) are frequently associated with autoimmune encephalitis (AE)…
Abstract Number: 2857 • 2016 ACR/ARHP Annual Meeting
Results from a Phase 0 Longitudinal Clinical Trial in Cutaneous Lupus Erythematosus: Analysis of the Type I IFN Signature in the Skin and Blood and Its Relationship with Disease Activity Scores and Autoantibody Profiles
Jessica Schreiter¹, Jarrat Jordan¹, Matteo Cesaroni¹, Marc Chevrier², Alexa Piantone³, Ian Gourley³, Jacqueline Benson¹ and Takahiro Sato¹, ¹Estrela Lupus Venture, Janssen Research and Development, LLC., Spring House, PA, ²Janssen Research and Development, LLC, Collegeville, PA, ³Immunology Translational Medicine, Janssen Pharmaceutical Research and Development, LLC, Spring House, PA
Background/Purpose: Type I IFN (IFN-I)-regulated gene expression is known to be elevated in blood and skin lesions of patients with two different forms of cutaneous…
Abstract Number: 2927 • 2016 ACR/ARHP Annual Meeting
Mechanisms Regulating the Loss of Tregs in CD11c-Flip-KO Mice That Contribute to the Spontaneous Development of Inflammatory Arthritis
Qi Quan Huang¹, Renee E. Doyle², Robert Birkett¹, Deyu Fang³ and Richard M. Pope², ¹Medicine/Rheumatology, Northwestern University Feinberg school of Medicine, Chicago, IL, ²Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: CD11c-Flip-KO (HUPO) mice spontaneously develop inflammatory, erosive arthritis. We previously demonstrated that T regulatory cells (Tregs) were reduced in HUPO mice and that the…
Abstract Number: 2934 • 2016 ACR/ARHP Annual Meeting
Clinical Assessment of the Monoclonal Anitbody, PRX003, a Potential Novel Treatment for Th17-Mediated Inflammatory Disease
Gene G. Kinney¹, Kenneth Flanagan¹, Michael Skov¹, Ronald Goldblum², Sue Griffith³, Robin M. Barbour¹, Wagner Zago¹, Ted Yednock¹, Martin Koller¹ and Dan Ness¹, ¹Prothena Biosciences Inc, South San Francisco, CA, ²Carlsbad Pharmaceutical Consulting, Inc., Carlsbad, CA, ³ClinPharma Services, Inc, San Diego, CA
Background/Purpose: Melanoma cell adhesion molecule (MCAM; CD146) is expressed on the surface of Th17 cells, which have the capacity to produce IL-17 and a multitude…
Abstract Number: 764 • 2016 ACR/ARHP Annual Meeting
Atacicept: Integrated Safety Profile from Phase II Randomized Placebo-Controlled Studies in Autoimmune Diseases
Patricia Fraser, Wai Chin and Amy Kao, EMD Serono, Billerica, MA
Background/Purpose: Atacicept, a recombinant fusion protein, targets both BLyS (B lymphocyte stimulator) and APRIL (a proliferation-inducing ligand), B cell activating factors involved in the pathogenesis…
Abstract Number: 1008 • 2016 ACR/ARHP Annual Meeting
Advantageous Effect of an Endogenous Retroviral Envelope Protein in Systemic Lupus Erythematosus with Ex Vivo and In Vivo Anti-Inflammatory Potential
Anne Troldborg^1,2, Magdalena Janina Laska³, Ellen-Margrethe Hauge^4,5, Shervin Bahrami⁶ and Kristian Stengaard-Pedersen^7,8, ¹clinical medicine, Aarhus University, Aarhus, Denmark, ²Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Biomedicine, Aarhus University, Aarhus, Denmark, ⁴Dept. of Anatomy, Aarhus University, Aarhus, Denmark, ⁵Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁶Clinical Medicine, Aarhus University, Aarhus, Denmark, ⁷Clinical medicine, Aarhus University, Aarhus, Denmark, ⁸Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Human Endogenous Retroviruses (HERVs) are remnants of retroviral infections in the human germline. Most, but not all, HERV genes have become inactive by accumulation…
Abstract Number: 1029 • 2016 ACR/ARHP Annual Meeting
Functional Genetics of PTPN2 in Rheumatoid Arthritis: Haploinsufficiency of PTPN2 Promotes Severity of Th17-Cell Mediated Autoimmune Arthritis
Mattias N. D. Svensson^1,2, Karen M. Doody¹, Cristiano Sacchetti^1,2, Dennis J. Wu¹, Gisen Kim³, Annelie Hellvard⁴, Brith Bergum⁴, Piotr Mydel⁴, Mitchell Kronenberg³, Michel L. Tremblay⁵ and Nunzio Bottini^1,2, ¹Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, ²Department of Medicine, University of California, San Diego, La Jolla, CA, ³Developmental Immunology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, ⁴Clinical Science, Broegelmann Research Laboratory, Bergen, Norway, ⁵Goodman Cancer Centre, McGill University, Montréal, QC, Canada
Background/Purpose: Genome-wide association studies have linked polymorphisms in the PTPN2 locus to rheumatoid arthritis (RA). PTPN2 encodes the tyrosine phosphatase TC-PTP, an important regulator of…
Abstract Number: 1179 • 2016 ACR/ARHP Annual Meeting
The Impact of Autoimmune Disease in the Management and Prognosis of Acute Coronary Syndrome
Nuria Lozano-Rivas¹, Carlos Marras Fernandez-Cid², Francisco Jose Pastor Perez³, Pedro Flores-Blanco⁴, Miriam Gomez-Molina⁴, Alberto Bermudez⁵, Luis Francisco Linares², Javier Martinez Ferrin², Francisco Andrés Martinez-Angosto¹, Pablo Mesa del Castillo² and Sergio Manzano-Fernandez⁴, ¹Rheumatology, Hospital Virgen de la Arrixaca, murcia, Spain, ²Rheumatology, Hospital Virgen de la Arrixaca, Murcia, Spain, ³Cardiology, Hospital Virgen de la Arrixaca, Murcia, Spain, ⁴Cardiology, Hospital Virgen de la Arrixaca, murcia, Spain, ⁵Hospital Virgen de la Arrixaca, Molina de Segura (Mu, Spain
Background/Purpose: Patients with autoimmune diseases (AID) have a high burden of cardiovascular disease leading to premature morbidity and mortality. But it is unclear if it…
Abstract Number: 1244 • 2016 ACR/ARHP Annual Meeting
Establishing a Case Report Form (CRF) for Systemic Autoimmune Diseases Studies
Lorenzo Beretta¹, Laurence Laigle², Ricard Cervera³, Alessandro Santaniello¹, Julien Hervouet⁴, Chris Chamberlain⁵, Jacqueline Marovac⁵, Maria Juárez⁶, Javier Martín⁷, Sambasiva Rao⁸, Jacques-Olivier Pers⁹, Johan Frostegård¹⁰, Jerome Wojcik¹¹, Bernard R. Lauwerys¹² and Marta E. Alarcon Riquelme^13,14, ¹Scleroderma Unit, Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ²Institut de Recherches Internationales Servier, SURESNES CEDEX, France, ³Department of Autoimmune Diseases, Institut Clínic de Medicina i Dermatologia, Hospital Clínic de Barcelona, Barcelona, Spain, ⁴Institut de Recherches Internationales Servier, Suresnes cedex, France, ⁵UCB Pharma, Slough, United Kingdom, ⁶UCB, Slough, United Kingdom, ⁷Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, PTS-Granada, Granada, Spain, ⁸Sanofi Genzyme, Boston, MA, ⁹INSERM ERI29, EA2216, Université de Brest, Labex IGO, CHRU Morvan, Brest, France, ¹⁰Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ¹¹QuartzBIO, SA, Geneva, Switzerland, ¹²Pôle de pathologies rhumatismales inflammatoires et systémiques, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ¹³Center for Genomics and Oncological Research, Pfizer-University of Granada-Junta de Andalucia, Granada, Spain and Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁴Institute for Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Systemic autoimmune diseases (SADs) are heterogeneous conditions with peculiar characteristics that share several clinical features. It is suspected that SADs share similar molecular abnormalities,…
Abstract Number: 1313 • 2016 ACR/ARHP Annual Meeting
Rheumatologic Diseases in HIV-Infected Patients in the Post-Antiretroviral Therapy Era: The County Experience
Muhsen Al-ani¹, Yasir Abdulqader¹, Robert Myers¹, Napatkamon Ayutyanont‎², Bikash Bhattarai² and Konstantinos Parperis³, ¹Internal Medicine, Maricopa Integrated Health System and University of Arizona College of Medicine, Phoenix Campus, phoenix, AZ, ²Research, Maricopa Integrated Health System, phoenix, AZ, ³Rheumatology, Maricopa Integrated Health System and University of Arizona College of Medicine, Phoenix Campus, phoenix, AZ
Background/Purpose: HIV infection has been associated with a plethora of rheumatologic diseases, however there are only few studies in the US analyzing the frequency of…
Abstract Number: 1359 • 2016 ACR/ARHP Annual Meeting
New Markers for Celiac Disease: Anti-Neo-Epitope Human and Microbial Transglutaminases
Torsten Matthias¹, Sandra Neidhöfer², Patricia Jeremias¹ and Aaron Lerner³, ¹Aesku.Kipp.Institute, Wendelsheim, Germany, ²AESKU.KIPP.Stitute, Wendelsheim, Germany, ³B. Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
Background/Purpose: Microbial transglutaminase (mTg) and human tissue Tg (tTg) complexed to gliadin peptides present neo-epitopes. Antibodies against these complexes are called tTg neo-epitope and mTg…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].